Charles Kendall Stover

List of Publications by Year
in descending order

41	3,792	172457	265206
papers	citations	29 h-index	42 g-index

42	42	42	4940
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	19
2	Neutrophil Extracellular Traps Confine Pseudomonas aeruginosa Ocular Biofilms and Restrict Brain Invasion. Cell Host and Microbe, 2019, 25, 526-536.e4.	11.0	129
3	S.Âaureus Evades Macrophage Killing through NLRP3-Dependent Effects on Mitochondrial Trafficking. Cell Reports, 2018, 22, 2431-2441.	6.4	71
4	Neutralizing Alpha-Toxin Accelerates Healing of Staphylococcus aureus-Infected Wounds in Nondiabetic and Diabetic Mice. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	51
5	The Neutrophilic Response to Pseudomonas Damages the Airway Barrier, Promoting Infection by Klebsiella pneumoniae. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 745-756.	2.9	10
6	Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets. JCI Insight, 2018, 3, .	5.0	25
7	Enhancement of antibody functions through Fc multiplications. MAbs, 2017, 9, 393-403.	5.2	13
8	New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 346-358.	2.1	11
9	Mouse model of hematogenous implant-related Staphylococcus aureus biofilm infection reveals therapeutic targets. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5094-E5102.	7.1	70
10	Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs, 2017, 9, 240-256.	5.2	16
11	An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nature Communications, 2017, 8, 637.	12.8	45
12	Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae. Nature Communications, 2017, 8, 1991.	12.8	70
13	Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption. Scientific Reports, 2017, 7, 16065.	3.3	34
14	Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4. JCI Insight, 2017, 2, .	5.0	29
15	Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA. PLoS ONE, 2017, 12, e0170529.	2.5	11
16	Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 5640-5648.	3.2	38
17	S. aureus blocks efferocytosis of neutrophils by macrophages through the activity of its virulence factor alpha toxin. Scientific Reports, 2016, 6, 35466.	3.3	33
18	Staphylococcus aureus Î± toxin potentiates opportunistic bacterial lung infections. Science Translational Medicine, 2016, 8, 329ra31.	12.4	93

#	Article	IF	Citations
19	Target-Agnostic Identification of Functional Monoclonal Antibodies AgainstKlebsiella pneumoniaeMultimeric MrkA Fimbrial Subunit. Journal of Infectious Diseases, 2016, 213, 1800-1808.	4.0	47
20	Pseudomonas aeruginosaBacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide. Journal of Infectious Diseases, 2016, 213, 640-648.	4.0	25
21	Association of Biofilm Formation, Psl Exopolysaccharide Expression, and Clinical Outcomes inPseudomonas aeruginosaKeratitis. JAMA Ophthalmology, 2016, 134, 383.	2.5	25
22	Anti-Alpha-Toxin Monoclonal Antibody and Antibiotic Combination Therapy Improves Disease Outcome and Accelerates Healing in a Staphylococcus aureus Dermonecrosis Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 299-309.	3.2	45
23	Differential Expression and Roles of Staphylococcus aureus Virulence Determinants during Colonization and Disease. MBio, 2015, 6, e02272-14.	4.1	152
24	A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection Models. Antimicrobial Agents and Chemotherapy, 2014, 58, 4384-4391.	3.2	98
25	A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Science Translational Medicine, 2014, 6, 262ra155.	12.4	228
26	Epitope Mapping of Monoclonal Antibodies using Synthetic Oligosaccharides Uncovers Novel Aspects of Immune Recognition of the Psl Exopolysaccharide of Pseudomonas aeruginosa. Chemistry - A European Journal, 2013, 19, 17425-17431.	3.3	19
27	Staphylococcus aureus Alpha Toxin Suppresses Effective Innate and Adaptive Immune Responses in a Murine Dermonecrosis Model. PLoS ONE, 2013, 8, e75103.	2.5	73
28	Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. Journal of Experimental Medicine, 2012, 209, 1273-1287.	8.5	142
29	A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1737-1742.	7.1	136
30	Development of a liquid chromatography/mass spectrometry-based drug accumulation assay in Pseudomonas aeruginosa. Analytical Biochemistry, 2009, 385, 321-325.	2.4	57
31	Discovery of Antibacterial Biotin Carboxylase Inhibitors by Virtual Screening and Fragment-Based Approaches. ACS Chemical Biology, 2009, 4, 473-483.	3.4	84
32	Molecular Validation of LpxC as an Antibacterial Drug Target in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50, 2178-2184.	3.2	87
33	Mutations in the cueA gene encoding a copper homeostasis P-type ATPase reduce the pathogenicity of Pseudomonas aeruginosa in mice. International Journal of Medical Microbiology, 2005, 295, 237-242.	3.6	77
34	Loss of hemolysin expression inStaphylococcus aureus agrmutants correlates with selective survival during mixed infections in murine abscesses and wounds. FEMS Immunology and Medical Microbiology, 2003, 38, 23-28.	2.7	56
35	Potent, Novel in Vitro Inhibitors of thePseudomonasaeruginosaDeacetylase LpxC. Journal of Medicinal Chemistry, 2002, 45, 3112-3129.	6.4	115
36	A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.	27.8	971

#	Article	IF	Citations
37	Impact of the High-Affinity Proline Permease Gene (putP) on the Virulence of Staphylococcus aureus in Experimental Endocarditis. Infection and Immunity, 1999, 67, 740-744.	2.2	51
38	Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments. Molecular Microbiology, 1998, 30, 393-404.	2.5	272
39	Identification and Characterization of the PutP Proline Permease That Contributes to In Vivo Survival ofStaphylococcus aureusin Animal Models. Infection and Immunity, 1998, 66, 567-572.	2.2	76
40	Chapter 17. Recent Advances in the Chemistry and Biology of Anti-mycobacterial Agents. Annual Reports in Medicinal Chemistry, 1996, , 161-170.	0.9	10
41	Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature, 1994, 372, 552-555.	27.8	176